Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

(2020) Caron A. Jacobson et al.   JOURNAL OF CLINICAL ONCOLOGY

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

(2019) Ann-Marie E Bröske et al.   BLOOD

Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma

(2019) P. Skrabek et al.   Current Oncology

How I manage patients with relapsed/refractory diffuse large B cell lymphoma

(2018) Christian Gisselbrecht et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bispecific antibodies in haematological malignancies

(2018) Andreas Viardot et al.   CANCER TREATMENT REVIEWS

CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies

(2018) Marina Bacac et al.   CLINICAL CANCER RESEARCH

ASBMT Pharmacy Special Interest Group Survey on CAR T Cell Therapy Administrative, Logistical and Toxicity Management Practices in the United States

(2018) Zahra Mahmoudjafari et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

(2016) Min Zhu et al.   CLINICAL PHARMACOKINETICS

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity

(2013) Suyu Liu et al.   Annals of Applied Statistics